Task: Answer Verification
Input (English): Question: Do somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma?
Answer: Somatic ERCC2 mutations correlate with complete response to cisplatin-based chemosensitivity in muscle-invasive urothelial carcinoma, and clinically identified mutations lead to cisplatin sensitivity in vitro. Nucleotide excision repair pathway defects may drive exceptional response to conventional chemotherapy.
Output (English): yes